Objective: The present parallel randomised control trial evaluated the feasibility of a nurse-led psycho-educational intervention aimed at improving the self-management of prostate cancer survivors.
compared to 2014 (c. 47,000) . Survival rates of prostate cancer are also improving and are predicted to continue to do so, as a result of earlier diagnosis and treatment, making follow-up care one of the greatest prostate cancer-related challenges facing the National Health Service (NHS) in the decades to come (Smittenaar et al., 2016) .
The care needs of prostate cancer survivors are often complex and, if unmanaged, can have a substantial impact on quality of life.
Firstly, in common with other cancers, the diagnosis of prostate cancer is linked with a range of psychological symptoms and conditions, such as anxiety and depression (Armes et al., 2009; Ream et al., 2008) . Secondly, the most common categories of treatment (surgery, radiotherapy, hormone therapy or a combination thereof) can produce physical symptoms, such as sexual dysfunction, urinary or bowel incontinence, hot flushes and bone fracture (Shahinian, Kuo, Freeman, & Goodwin, 2005) . In turn, these physical symptoms then lead to a range of secondary psychosocial problems, such as increased anxiety, loss of identity, shame, social isolation, reduced physical activity, depression (Stein, Syrjala, & Andrykowski, 2008) .
Thirdly, a majority of prostate cancer patients live with multiple morbidities (e.g., diabetes, cardiovascular disease), which further compound their care needs and complicate the management (Crawford et al., 2011; Daskivich et al., 2013) . Moreover, psychosexual symptoms, anxiety and distress affect not only patients but also their families (Harden et al., 2013; Northouse et al., 2007; Segrin, Badger, & Harrington, 2012 ), resulting in a high level of complex, unmet needs.
The range and complexity of subsequent symptoms of prostate cancer survivors, together with the large volume of patients being diagnosed and treated are major challenges to improving the quality and consistency of post-treatment care.
The capacity of the traditional medical-led model of long-term follow-up care for cancer has been increasingly regarded as inadequate and unsustainable Watson et al., 2016) . As with other chronic conditions, the long-term management of cancer treatment side-effects is increasingly regarded as being best delivered by nurses, with specialist input provided when needed (CockleHearne et al., 2013; Jefford et al, 2013; Richardson, Griffin, Miller, & McNeil, 2008; Skolarus et al., 2014) . Nurse-led care has already shown to be effective in managing chronic conditions such as diabetes (Renders et al., 2000) , depression (Gilbody, 2004) and some cancers (Lewis et al., 2009) . This is unsurprising, considering that the management of multiple chronic conditions is part of the core skills of general practice nurses (NMC, 2015) , and leading cancer charities have recognised the opportunity to develop the nursing role in primary care and have set up educational programmes to prepare Practice Nurses for taking an enhanced role in managing cancer as a long-term condition (Macmillan Cancer Support, 2013) .
Building on recent work of the National Cancer Research Institute (NCRI) in the UK, novel and comprehensive holistic needs assessment instruments are available for cancer patients, but they have not been tested for prostate cancer. Prostate cancer is a strong litmus test for whether the use of such instruments and models of care-promising as they may be-are effective and cost effective when scaled-up at healthcare service level. Similar efforts have already shown some promising results (Watson et al., 2016) , and together with colleagues from Oxford we adapted and integrated local third sector models for use in the NHS. In line with Medical Research Council (MRC) guidelines for developing complex interventions (Craig et al., 2013) , before a fully powered evaluation of the nurse-led holistic care model can be recommended, questions need to be answered about its feasibility and acceptability. The present study aimed to: (1) assess the feasibility metrics of the intervention (patient recruitment, attrition and response rates), and its acceptability to patients; (2) pilot the intervention delivery, and collect process data, including the number of appointments needed to deliver the intervention, the duration of intervention delivery (planning, travel, patient-contact and administrative time), the range and severity of the symptoms addressed, and the support techniques used; (3) investigate the suitability of key clinical and cost-effectiveness measures for a future fully powered trial. Progression to a fully powered trial is predicated on the present study meeting the following predetermined targets: (a) a recruitment rate of at least 25% of the clinically eligible patients (invited to the trial); (b) an attrition rate of <20%; and (c) outcome measures completion rates above 66%.
| ME THODS
Trial of personalised care after treatment-prostate cancer (TOPCAT-P) is an individually randomised feasibility trial, comparing a personalised, nurse-led, psycho-educational intervention with the augmented usual care in North Wales.
| Participants
Eligible participants (N = 305) were identified from hospital records by a team led by the Urology Advanced Nurse Practitioner, and were biochemically stable incident prostate cancer patients, 9-48 months post-diagnosis, at the end of radical curative treatment (surgery, radiotherapy), hormone therapy, or deemed unlikely to receive further treatment (watchful waiting). The study excluded men awaiting curative treatment or monitored until proof of progression (active surveillance), in the terminal stage of their disease, who lacked capacity, or with cognitive, visual or neurological impairments that would impede completing the trial (as assessed by the referring clinician).
Ninety-five participants were recruited by blinded selection and individually randomised to Intervention (N = 48) or Control (N = 47) groups, on a 1:1 basis and balanced for age quartiles (see ; Supporting Information Appendix S1). Participant allocation was revealed to patients and researchers after recruitment.
| Intervention
Participants in the Control group continued to receive their usual care delivered outside of the trial, and a Macmillan Organiser to self-record and monitor physical and psychological symptoms.
Patients in the Intervention group received the above, followed by an initial appointment with the Research Nurse for a holistic needs assessment, and as many tailored follow-up appointments as appropriate (by agreement with the Research Nurse). Further details about the training undertaken by the nurse, the rationale and the description of the intervention have already been published .
| Outcome measures
Patient self-reported outcome measures assessed changes in physical symptoms (EPIC-26, Expanded Prostate Cancer Index Composite; Szymanski, Wei, Dunn, & Sanda, 2010) , psychological well-being (Hospital Anxiety and Depression Scale; Zigmond & Snaith, 1983) , confidence in managing own health (Lorig, Sobel, Ritter, Laurent, & Hobbs, 2001 ), medical and support needs (Supportive Care Needs Survey-simplified response format; Boyes, Girgis, & Lecathelinais, 2009; Schofield, Gough, Lotfi-Jam, & Aranda, 2012) , and general health and quality of life (EuroQoL EQ-5D-5L; Brooks, 1996) . The patients' satisfaction with the healthcare services was a secondary outcome measure, and consisted in ratings on a five-point Likert scale anchored at "Not at all satisfied" and "Totally satisfied." This measure was developed and first used in the PROSPECTIV trial, and included with the authors' permission (Watson et al., 2016) . The Recruiting Officer administered the baseline measures to all patients after consent, and prior to randomisation. Subsequent questionnaires were sent by post to be completed by patients in both arms and similarly returned to the research team by post (see Table 1 ).
The use of health and social care services during the intervention was measured at 12, 24 and 36 weeks using a purpose-built Client Service Receipt Inventory (CSRI), documenting the frequency and types of contacts with health, social and Third Sector providers.
Relevant medical history data (e.g., cancer diagnosis, comorbid conditions) were collected from GP records with patients' consent. TA B L E 1 Timeline of intervention delivery and outcome measures 
TA B L E 2 Feedback interview schedule for patients and GPs
The main topics of the interview schedule for patients:
(1) experience of the intervention (perceived benefits, missed opportunities and possible broader impact) (2) information received about prostate cancer survivorship (3) views on the routine usual care received from the National Health Service (4) feedback on improving the intervention (timing, location, and delivery) (5) feedback on completing the research trial (communication with research staff, outcome measures completion, other aspects of participant burden)
The main topics of the interview schedule for GPs:
(1) the impact of the intervention on patients seen in general practice
(2) the impact of the intervention on GPs' own work (3) the communication with the research nurse (including the patients' holistic needs assessment and personalised care plan)
| Feedback interviews
A purposive sample of patients in the Intervention arm (N = 25) and
GPs whose patients received the intervention (N = 3) took part in feedback interviews 5-9 months after the end of the study. The patient sub-sample was proportionate with the Intervention group for age, cancer stage at diagnosis, treatment type and level of need. GPs were selected among those who had the largest number of patients in trial. Interviews were semi-structured (see Table 2 ) and conducted by a researcher not involved in the intervention delivery.
The risk assessment identified a low impact risks for patient safety, with a low probability. An independent data monitoring group was not required for this pilot and feasibility study, and interim analyses were not conducted. Provisions were made to record all adverse events and serious adverse events and to follow them up for the duration of the study or until resolution. Data management strategy is reported elsewhere .
| Data analysis
Feasibility metrics were assessed against the predetermined progression criteria. Intervention delivery and process evaluation data were analysed descriptively. The preliminary analysis of proposed outcome measures followed an intention-to-treat approach and is reported descriptively. Limited exploratory inferential analyses are reported in text for secondary outcome measures.
The exploratory health economics analysis adopted a societal perspective due to the expected broad impact of the intervention on the NHS (both primary and secondary care), the patients, their families and the third sector. The costing analysis used the national unit costs (Curtis, 2014) .
The feedback interviews were analysed using a thematic framework approach (Ritchie & Spencer, 1994; Ritchie, Spencer, & O'Connor, 2003) . Two researchers coded the data and identified recurrent themes manually using printed transcripts, in two stages, firstly determining overall themes, and secondly, more specific trends and patterns in the data. Difference between coders was discussed and settled by agreement. The patients' and GPs' interviews were analysed separately.
| RE SULTS

| Feasibility metrics, randomisation, baseline demographic and clinical characteristics
Between November 2013 and April 2014, 1,469 cases were screened for eligibility, and all 305 eligible patients were invited to take part in the trial, in two letters sent to them by their treating clinician.
The reasons for ineligibility are included in Supporting Information
Appendix S2. Ninety-five patients were recruited from January 2014
to July 2014, (recruitment rate 31.15%; 95% CI: 25.95%-36.35%), thus, meeting the target of recruiting at least 25% of eligible patients (see Table 3 , for baseline demographics and clinical characteristics).
Five patients declined to participate (1.64%; 95% CI: 0.21%-3.07%) and 205 patients did not respond (67.21%; 95% CI: 61.94%-72.48%).
The flow of participants through the trial is presented in Figure 1 . Completion rates of outcome measures were high for all questionnaires: 100% for the baseline assessment prior to randomisation for both groups, 92% and 87% (Intervention and Control groups respectively) for the follow-up assessment (main outcome measures), 88% and 89% for the CSRI (see for details Supporting Information Appendix S2). All completed questionnaires were included for analysis. Overall, the target completion rate of at least 66% of the recruited participants was achieved for all individual measures in each group, both at baseline and follow-up.
| Intervention delivery
The intervention was delivered successfully to all participants (N = 45) without significant adverse events, over a total of 123 hr of patient contact. Overall, the intervention delivery required approximately 10 hr of nurse time per patient (587 min), with a larger share of the time taken by administrative duties (see Table 4 Almost half of the symptoms identified in the intervention had never been reported to a healthcare professional before (with reasons included in Supporting Information Appendix S3), and the majority of the symptoms reported previously to clinicians were physical rather than emotional. Symptoms had previously been first reported in secondary care (54%) or to the GP (44%), with attempts to address symptoms having had a varied outcome: a third improved Note. HNC: Higher National Certificate; HND: Higher National Diploma or resolved, another third failed to improve, but patients reported improved coping, and for the final third both symptoms and patient coping remained unchanged.
The most frequently used component of the intervention was teaching self-management strategies (72%). On fewer occasions, participants received information materials (14%), and were signposted (13%) or referred (1%) to other services. The most commonly taught self-management strategies were aimed at improving the recognition of symptoms and the development of coping strategies (e.g., symptom selfmonitoring, life-style adjustment, cognitive reappraisal). Information materials were most often offered in relation to physical symptoms, such as urinary incontinence, sexual dysfunction and sleep/fatigue problems. Signposting was most often to the GP (38%), Third Sector organisations (29%) or local patient support groups (28%).
| Intervention outcome measures
Follow-up primary outcome measures data were analysed using
ANCOVAs controlling for baseline levels (see Supporting Information
Appendix S4 for details). Summary results are reported in Table 5 , However, some of the dimensions showed very little change and this will likely inflate the sample to an unachievable size. For example, the effect size for hormonal symptoms was 0.1, and with a reduced significance level of 1% to accommodate the five dimensions, this approach would require a sample of 5,954 at 90% power. As it is likely that the analysis in a future trial will incorporate the baseline measurements, an ANCOVA would be appropriate, with an estimated minimum sample of 88 or 3,418 participants respectively.
The participants' satisfaction with key elements of follow-on cancer care (the intervention's secondary outcome measure) was similar at baseline between the two groups, and seemed to improve marginally for the Intervention group at follow-up (Mann-Whitney 
| Health economics analysis
Two sources of data for economic evaluation were used and compared for agreement: a bespoke CSRI questionnaires and selected extracts of GP records. Overall, there was a strong agreement
showing the flow of participants through each phase of the trial of personalised care after treatment-prostate cancer trial between respondents' self-reported data and GP records data, with values ranging from 66.25% to 90.00% (see Supporting Information
Appendix S5 for details).
The EQ-5D-5L response rate was 100% at baseline and 88.4%
at follow-up. Both participant groups reported similar EQ-5D-5L
score distributions (median and interquartile range) at baseline and follow-up, for each domain (see Supporting Information Appendix S5), with a non-significant mean QALY gain of 0.0191 (bootstrapped 95% CI: −0.0371 to 0.0774) in favour of the Intervention group (see Table 6 ).
In the absence of a significant difference in the primary outcome measures, we performed an exploratory cost-consequence analysis TA B L E 4 The duration of the intervention (in minutes), and the distance travelled (in miles) per patients and per appointment (Drummond, Sculpher, Claxton, Stoddart, & Torrance, 2015) . This included the complete data (at baseline and follow-up) of 80 participants (84.2% of the clinical sample), and used published national average unit costs for the UK for the year 2013/14 (Department of Health, 2015) . Any costs from previous years were inflated to 2013/14 using the Hospital & Community Health Service inflation indices from the national average unit costs.
The mean total cost per participant in the Intervention group was £847 (including the cost of delivering the intervention: £354) and £529 for the Control group over the 9 month period between baseline and follow-up. Thus, the net cost of the intervention was £317
(bootstrapped 95% CI: £46-£558). Further details of the health economic analysis are included in Supporting Information Appendix S5.
| Feedback interviews with patients and GPs
The patient interviews revealed four major themes: ( 
| D ISCUSS I ON
All feasibility and acceptability targets were achieved during the study. Feedback questionnaires with patients and GPs revealed a TA B L E 6 Self-reported EQ-5D-5L index scores, mean QALYs and incremental mean QALYs at 9 months follow-up by group (N = 80) 
| Implication for a future delivery of the intervention
Three major elements of care provided by the intervention should inform future practice. Importantly, the intervention nearly doubled the number of cancer survivorship symptoms ever reported by participants, and the underreporting of symptoms by cancer survivors is well-known (Breetvelt & Van Dam, 1991; Ristvedt & Trinkaus, 2005) .
The range of reasons why patients failed to report the symptoms previously was varied, but two critical elements seemed to be a structured consultation (i.e., "clinician had not asked"), and sufficient time. Moreover, a quarter of patients continued to reveal symptoms, beyond those initially reported in the comprehensive self-screening instrument used in the trial. Notably, these were common, high-burden symptoms, which were arguably top-of-mind for patients, such as urinary incontinence, sexual dysfunction and bowel problems.
Thus, the reasons for the initial under-reporting may be psychological. The rapport and continuity of care provided by the research nurse may have facilitated their subsequent reporting. It was beyond the aim of the present study to establish why patient under-report obvious and significant prostate cancer sequelae. However, alongside a structured consultation and sufficient time (mentioned by patients during the intervention), continuity of care seems to be a third essential component of follow-up care (as identified by patients in the feedback interviews).
Risk stratification is often employed to identify patients with "highest need" and selectively target interventions to improve their effectiveness (Watson et al., 2012) . However, this was not supported by the present data. Firstly, as discussed earlier, almost half of the symptoms assessed and managed in the intervention had not been reported before, thus, restricting the patients' access to the intervention would result in many patients and their unmet needs being missed. Secondly, the sensitivity of screening instruments is inherently limited. This was highlighted presently when patients failed to identify common and high-burden symptoms initially, but did so eventually throughout the trial. Therefore, a stratification of needs prior to the exploration of symptoms and concerns is likely to miss a significant number of patients and unmet needs, many of which might have never been reported before.
The effectiveness of the intervention could potentially be increased by improving the timing of its delivery. There was no single time point preferred by all the patients, but the data suggested that possibly many would benefit from having the extra psychological support and information available earlier in the cancer pathway, soon after diagnosis and before the treatment decision. This would allow patients to access the support, as needed, at any point (a) after diagnosis, and before deciding on the treatment option, (b) after the end the of the treatment, and (c) for some patients even some time after the end of the treatment. The difference from current usual practice is that the holistic needs assessment would need to be made available at an earlier stage (after diagnosis), and followed-up with psychological support and information if-and-when needed. As the patient progresses through the cancer pathway, the holistic needs assessment could be updated (e.g., at the end of the treatment, or later in the recovery period, by agreement between patient and clinician). As
shown in the present feasibility trial, giving patients the opportunity to complete a holistic needs assessment raises their awareness of possible psychological and physical concerns. This, in turn, makes it more likely for patients to report symptoms earlier and seek adequate management or coping strategies. Beginning this assessment and management process early is likely to produce a greater improvement in the patients' quality of life than an intervention delivered once patients are ready for discharge from secondary care.
| Methodological implications for future research
The administrative burden in this trial was high, but can be improved in a future fully powered trial, by using simpler, electronic case report forms, which can be completed immediately after the appointment (e.g., on a tablet or portable computer). The nurse planning time was approximately one quarter of the patient contact time, and was used by the nurse to review the patient documentation, plan the upcoming appointment, and prepare the information materials related to the symptoms and relevant self-management techniques.
This process too could be optimised further, as the range and frequency of the information materials needed can be estimated from the extensive results of the current trial.
| CON CLUS IONS
TOPCAT-P confirmed that the level of need of prostate cancer survivors is varied, and in many cases, substantial, having a considerable impact on quality of life. The successful feasibility trial suggested incremental improvements to the intervention and usual care.
However, the fundamental questions regarding the effectiveness and cost-effectiveness of these changes remain to be answered by a future fully powered trial.
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